![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Soft-tissue sarcomas (STS) are a heterogeneous group of rare solid tumors of mesenchymal origin. This paper reviews the current status of systemic treatment in advanced and metastatic soft tissue sarcomas, with an emphasis on trabectedin. Trabectedin is a unique type of chemotherapeutic agent with multiple potential mechanisms of action. We discuss the putative mechanisms, as well as the toxicity and administration schedules of trabectedin, followed by its efficacy in first-line systemic therapy and beyond first-line systemic therapy.
Disclosure
WvdG received speaker’s fee from Eli Lilly and Novartis and institutional research grants from Novartis and GSK. RJ has consulted for the following: Pharmamar, JJ, Adaptimmune, Eisai, Daichii Sankyo, Imclone/Lilly, Immodulon, Immunedesign, Merck, and Morphotek. The authors report no other conflicts of interest in this work.